Document is current
Any future updates will be listed below
-
Authors
Dubol, Manon
Wikström, Johan
Lanzenberger, Rupert
Epperson, C. Neill
Sundström-Poromaa, Inger
Comasco, Erika
-
Funding
Funding for this research was provided by:
Uppsala University
- License Information
-
More Information
Article History
Received: 2 August 2021
Accepted: 8 February 2022
First Online: 9 April 2022
Competing interests
: RL received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. CNE has served on the advisory board of Asarina Pharma and Sage Therapeutics and has received research funding from and served as a consultant and advisory board member for Sage Therapeutics. ISP has served occasionally on advisory boards or acted as invited speaker at scientific meetings for Asarina Pharma, Bayer Health Care, Gedeon Richter, Peptonics, Shire/Takeda, Sandoz, and Lundbeck A/S. All other authors declare that they have no conflict of interest.
